Navigation Links
Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
Date:8/3/2010

SAN DIEGO, Aug. 3 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) announced the online publication of results from its COR-BMOD trial of Contrave® (naltrexone SR/bupropion SR) in the journal Obesity. The COR-BMOD trial evaluated intensive behavior modification (BMOD) plus Contrave32 (32mg naltrexone sustained release (SR)/360mg bupropion SR) compared to BMOD plus placebo, in 793 overweight or obese patients. The addition of Contrave to BMOD delivered significant incremental weight loss and improvements in measures of cardiometabolic risk.  Results showed that patients taking Contrave lost 9.3% of their body weight compared to 5.1% for patients on placebo (p< 0.001), on an intent-to-treat basis.  For those who completed 56 weeks of treatment, patients taking Contrave plus BMOD lost 11.5% of their body weight compared to 7.3% for those taking placebo (p<0.001).

Behavior modification, including diet and exercise, has long been considered the standard of care in managing obesity.  The benefit of adding specific pharmacotherapies to a rigorous BMOD program has not been extensively evaluated.  COR-BMOD was designed to test this hypothesis by evaluating Contrave in a setting conducive to maximum weight loss in which patients used the medication as part of a broader weight-loss effort.  Participants in both groups received diet and exercise counseling during 28 small group sessions with one or two professionals, each lasting 90 minutes, over the course of the year-long trial.

"There is no magic bullet for the treatment of obesity.  For some patients, effective and sustainable treatment is going to require a multi-modal approa
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
2. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
3. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
4. Cornerstone Therapeutics Licenses Alpha-7 Technology to Targacept
5. Cornerstone Therapeutics Announces Collaboration with The Cough Company
6. Hepatitis C Therapeutics Market - Taiwan
7. Amicus Therapeutics to Host Its Second Quarter 2010 Financial Results Conference Call and Webcast on August 5, 2010
8. Abviva Announces Notice of Canadian Patent for Technology Used in Breast Cancer Diagnostics and Therapeutics
9. MabVax Therapeutics Initiates Phase II Clinical Trial of Vaccine to Prevent Recurrent Sarcoma
10. Cornerstone Therapeutics to Host Second Quarter 2010 Conference Call
11. Richard B. Brewer Joins Nile Therapeutics as Executive Chairman of the Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , September 19, 2014 ... by Equipment Type (Benchtop, Mobile, Industrial, & Laboratory), ... Technology (Tray-style, Manifold, & Rotary) & Geography - ... MarketsandMarkets, defines and segments the lyophilization market on ... with analyses and projections of the market size ...
(Date:9/19/2014)... Fla. , Sept. 19, 2014  The body ... with the publication of two papers this past week.  ... – Head and Neck Surgery , finds that ... and subjective measures of sleep disordered breathing, leading the ... reduction in obstructive sleep apnea severity and improvement of ...
(Date:9/19/2014)... and CAMBRIDGE, Mass. , Sept. 19, ... (PGDx), a provider of advanced cancer genome analysis ... a leader in discovering and developing highly selective ... the first-ever comprehensive genomic study of malignant mixed ... of the female reproductive system, also known as ...
Breaking Medicine Technology:Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
... Medical, Inc., the wholly-owned operating subsidiary of Patient ... the recently released 2011-2012 U.S. News and World ... of the SurgiCount Safety-Sponge® System, a clinically proven ... common surgical errors, retained surgical sponges.  Only 17 ...
... A new policy recommendation released on 20 July by ... of serological (blood) tests to diagnose active tuberculosis (TB). ... are different to QuantiFERON, which measures responses of white ... Active tuberculosis occurs when the TB organism has overcome ...
Cached Medicine Technology:SurgiCount Medical Announces Expanded Honor Roll Hospital Users, Landmark Product Usage Milestones Achieved 2SurgiCount Medical Announces Expanded Honor Roll Hospital Users, Landmark Product Usage Milestones Achieved 3Cellestis Responds to World Health Organization Guidance on Use of Blood Tests for Active Tuberculosis 2Cellestis Responds to World Health Organization Guidance on Use of Blood Tests for Active Tuberculosis 3Cellestis Responds to World Health Organization Guidance on Use of Blood Tests for Active Tuberculosis 4
(Date:9/20/2014)... 20, 2014 “Motherhood is a wonderful gift ... in their latest article , “We know that you ... can—and that’s what we want to do as well.” , ... and should expect from their Family Physicians who practice obstetrics ... new motherhood. , To learn more about Community Health ...
(Date:9/19/2014)... “Copay coupons,” a drug manufacturer marketing tactic often ... with prescription drug coverage, may now be infiltrating Medicare ... from the Department of Health and Human Services Office ... suppliers from offering side-payments to increase sales of goods ... report highlights that two recent surveys, including one by ...
(Date:9/19/2014)... York, NY (PRWEB) September 19, 2014 ... PR News at the Platinum PR and Top Places ... Hyatt in New York City. Camino received honorable mentions ... Shoestring Campaign” — for its work elevating Latina voices ... this incredible organization and be a part of its ...
(Date:9/19/2014)... 19, 2014 According to a report ... embattled blood-thinner Xarelto, named as defendants in several lawsuits ... have moved the court to dismiss those suits because ... sufficient connection with Philadelphia.* The cases include, for instance, ... 140304328; Pa. Comm. Pls., Philadelphia Cty.), which was brought ...
(Date:9/19/2014)... (HealthDay News) -- Although there is mounting evidence ... middle-aged and older adults in the United States ... to new research. Less than one-quarter of ... by the Department of Health and Human Services, ... for promoting health and fitness and staying independent, ...
Breaking Medicine News(10 mins):Health News:Newest Article from Community Health Center of Snohomish County Highlights The Importance of Proper Health Care for Expectant Mothers 2Health News:PCMA: New OIG Report Cites Drug Manufacturer“Copay Coupon” Use in Medicare Part D 2Health News:Camino Public Relations Honored for Raising Latina Voices in National Health Care, Immigration Debates 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 3Health News:Adults Over 45 Not Meeting U.S. Muscle Strengthening Guidelines, Study Says 2
... July 24 /PRNewswire-Asia/ -- Neusoft Medical Systems Co.,Ltd. (Neusoft ... announced that its newly developed Computed,Tomography(CT) system, NeuViz 16 ... and is also marked as the first of its ... was shipped to its U.S.-based customers,recently, Neusoft Medical has ...
... offer a medical heads-up, study says, , FRIDAY, July ... trauma patients could help medical personnel identify those at ... study says. , People who abuse alcohol often ... about potentially serious health needs. But even if people ...
... , , , ... ) will provide free access for the uninsured and underinsured to ... p.m. Saturday and Sunday, July 25 and 26, at the W.O. Walker ... sponsored by MedWorks and will provide 1100 medical, 300 vision and 200 ...
... 24 Dialysis Corporation of America (Nasdaq: DCAI ) ... results on Wednesday August 5, 2009, after the close of the ... with its second quarter 2009 earnings release the following morning, Thursday, ... , Those interested in participating in the August ...
... ANN ARBOR, Mich., July 24 As the economy continues ... choices about how to spend what money they have, and children -- ... bracket -- are more at risk because of it. , ... Children,s Health taken in May 2009 shows 44 percent of families, financial ...
... , , , ... DVA ), a leading provider of kidney care services for those ... dialysis facilities in Colorado have received the 2009 End Stage Renal ... granted by the Intermountain ESRD Network (Network 15), a federally mandated, ...
Cached Medicine News:Health News:Neusoft Medical's Latest Innovation, NeuViz 16 CT Scanner, Approved by FDA for the U.S. Market 2Health News:Neusoft Medical's Latest Innovation, NeuViz 16 CT Scanner, Approved by FDA for the U.S. Market 3Health News:Alcohol and Trauma: Blood Test Gets to the Truth 2Health News:U.S. Senator Sherrod Brown to Lend Support at MedWorks' Free Medical Clinic This Weekend 2Health News:Dialysis Corporation of America Announces Second Quarter 2009 Earnings Release Date 2Health News:Recession Stressful for Many Kids, Toughest on Poor and Uninsured 2Health News:Recession Stressful for Many Kids, Toughest on Poor and Uninsured 3Health News:Six DaVita Clinics in Colorado Receive Silver Award for Clinical Excellence 2Health News:Six DaVita Clinics in Colorado Receive Silver Award for Clinical Excellence 3
BD Vacutainer® Heparin Tubes are spray-coated with either lithium heparin or sodium heparin and are used for plasma determinations in chemistry....
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
... Coagulation tubes contain a buffered ... available with a citrate concentration ... 0.129 mol/l (3.8%). The mixing ... solution to 9 parts blood. ...
... are available in two versions. ... a clotting activator and is ... serum is required for testing ... is suitable where the testing ...
Medicine Products: